Ibrutinib, also known as Ibrutinib, is a new type of small molecule tyrosine kinase inhibitor that is widely used to treat certain types of leukemia and lymphoma. Ibrutinib was developed and produced by an outstanding American biopharmaceutical company Janssen Biotech, Inc., and Pharmacyclics LLC, an AbbVie company and was approved by the U.S. Food and Drug Administration (FDA) in 2013, becoming the first FDA-approved oral targeted drug for the treatment of B-cell leukemia. This is proving very good treatment but the ibrutinib price in Malaysia, Philippines has higher.

When using ibrutinib, you should follow the doctor's advice and do not adjust the dose or stop the drug without authorization. At the same time, since ibrutinib may cause certain adverse reactions, such as rash and nausea, please pay close attention to the patient's physical condition, be aware of any abnormal reactions in the patient at any time, and contact the doctor in time for guidance.